The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos.
Severe ovarian hyperstimulation syndrome complicates up to 6% of IVF treatment cycles. We have utilized our pre-embryo cryopreservation program to manage incipient ovarian hyperstimulation syndrome in an alternative way. Four women, who were at risk of developing ovarian hyperstimulation syndrome, underwent oocyte retrieval, but not embryo replacement. Instead, resulting pre-embryos were cryopreserved for future transfer. The four patients have since become pregnant. Three conceived after thawed embryo replacement cycles, and the fourth conceived spontaneously 1 month after the stimulation cycle. This approach offers maximum flexibility in the management of ovarian hyperstimulation syndrome.
Amso
N N
NN
Academic Department of Obstetrics and Gynaecology, Royal Free Hospital, London, United Kingdom.
Ahuja
K K
KK
Morris
N
N
Shaw
R W
RW
D000328:Adult; D002064:Buserelin / Q000009:adverse effects*; D015925:Cryopreservation; D004622:Embryo, Mammalian; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D006080:Ovarian Follicle / Q000187:drug effects*; D010062:Ovulation Induction / Q000009:adverse effects*; D011374:Progesterone / Q000097:blood
D011374:Progesterone; D004958:Estradiol; D002064:Buserelin